Publications and Abstracts

  1. Tahir H, Rahman N, Thilaganathan B, Nicolaides K. Levels and regulation of SHBG, Testosterone and Oestrogen in foetal serum.Abstract Medical Research Council, 1993

  2. Tahir H, Thomas G, Sheerin N, Pattison JM, Goldsmith DJA. Successful medical treatment of acute bilateral emphysematous pyelonephritis. American Journal of Kidney Diseases, Vol 36, No 6, 2000: 1267-1270

  3. Tahir H, Allard S, Jawed S. Spontaneous Hydropneumothorax in a man with rheumatoid arthritis. Rheumatology 2001; 40: 232-233

  4. Tahir H, Herring R, Gendi N, Maddison V, Gordon T, Dasgupta B. Effectiveness and safety of anti-TNF therapy in clinical practice Experience from South Essex. Abstract, British Society of Rheumatology meeting April 2002

  5. Farzaneh-Far R, Watkins J, Tahir H, Wykes F, Beynon H. Small vessel vasculitis with pulmonary aneurysms and silent myocardial infarction. Rheumatology 2003; 42(8):1022-4

  6. Watkins J, Tahir H, Farzaneh-Far R, Wykes F, Beynon H. Jo-1 syndrome with associated poorly differentiated adenocarcinaoma. Rheumatology 2004; 43(3):389-90.

  7. Tahir H, Isenberg D. Novel Therapies in Lupus Nephritis. Lupus 2005; 14(1):77-82.

  8. Tahir H, Rohrer J, Bhatia A, Wegener B, Isenberg DA. Humanised anti CD 20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibody against rituximab. Rheumatology 2005 Apr; 44(4):561-62

  9. Allen P & Tahir H, A case report of how easily malaria can be missed. J R Soc Med.2006; 99: 201-202

  10. Tahir H & Iqbal Z. Do doctors who volunteer their services in disasters overseas do more harm than good? BMJ 2006;332:244

  11. Irving KS, Sen D, Tahir H, Pilkington C, Isenberg DA..A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus – A retrospective review of cases. Rheumatology. 2007;46(7):1171-3

  12. Tahir H, Moore S, Ehrenstein MR. Comparison of anti-TNF therapy in Daily Practice. Rheumatology Abstract 2006

  13. Shenker NG, and Tahir H . Vitamin D levels should not be included in the routine laboratory tests for screening patients with fibromyalgic symptoms. Rheumatology 2007 Abstract (322)

  14. Cooney M, Doyle DV, Greenwood M, Hakim AJ, Shenker N, Tahir H. An audit of efficacy, side effects and withdrawals for Infliximab and Etanercept in the treatment of RA Rheumatology Abstract 2007

  15. Greenwood M, Cooney M, Rooney M, Hakim AJ, Tahir H. A Retrospective Comparison of the Three Year Outcome of Etanercept and Infliximab for Rheumatoid Arthritis in Clinical Practice. Rheumatology 2008; 47(4): #136

  16. Greenwood M, Cooney M, Rooney M, Hakim AJ, Tahir H. A Comparison of the Two Year Outcome of Etanercept as a First and Second Anti-TNF Alpha Agent in Clinical Practice. Rheumatology 2008; 47(4): #109

  17. Cooney M, Greenwood M, Rooney M, Tahir H, Hakim AJ. 12 Months Experience of Etanercept in the treatment of Psoriatic Arthritis. Rheumatology 2008; 47(4): #227

  18. Greenwood MC, Hakim AJ, Donnelly SP, Rooney MM, Tahir H. Comparing outcome for the first 12M of anti-TNF therapy in RA in a standard UK clinical practice. Greenwood MC, Hakim AJ, Donnelly SP, Rooney MM, Tahir H. Rheumatology, April 2009;48;i63 (114)

  19. Greenwood MC, Donnelly SP, Rooney MM, Hakim AJ, Tahir H. 4yr outcome data in RA patients receiving either Etanercept or Inflixamab in standard clinical practice. Rheumatology, April 2009;48; i64(119)

  20. Penn H, Greenwood MC, Hakim AJ, Donnelly SP, Tahir H. An audit of TB prophylaxis for anti-TNF traeted patients in secondarycare in East London- is the BTS guidance useful? Rheumatology, April 2009;48;i113(276)

  21. Greenwood M, Farooqui O, Hakim AJ, Donnelly SP, Rooney M, Lanham JG, Tahir H. ANKYLOSING SPONDYLITIS AND ANTI-TNF a:EXPERIENCE IN CLINICAL PRACTICE POST 2008 NICE GUIDANCE. Rheumatology 2010:49;i51

  22. Hasson R, Mulcahy V, Tahir H. Amlodipine poisioning complicated with acute non-cardiogenic pulmonary oedema .BMJ Case Reports Published 5 September 2011;2011:published online 5 September 2011, doi:10.1136/bcr.07.2011.4467

  23. Iqbal Z, Tahir H. Common Sports related Infections. In Clinical Sports Medicine (McGraw-Hill Sports Medicine). Brukner P & Khan K. Chapter 56, 4th Edition, 2011

  24. Housman L, Arden N, Schnitzer TJ, Birbara C, Conrozier T, Skrepnik N, Wei N, Bockow B, Tahir H, Hammond A, Bailleul F. Intra-articular hylastan versus steroid for knee osteoarthritis .Knee Surgery, Sports Traumatology, Arthroscopy February 2013

  25. Donnelley S, Baird K, Ismail L, Greenwod M, Tahir H. The Ottawa ankle rules to prevent unnecessary radiology: experience in a busy emergency dept in the UK. Submitted emergency medical journal 2013

  26. Tahir H, Donnelly S, Greenwood M. A Phase 4 pilot study to establish whether an intramuscular steroid injection is as effective as an intralesional steroid injection in the treatment of tennis elbow. Rheumatology 2013; i160, 276

  27. Adshead R, Cambridge S, Donnelley S, Tahir H. Earl Inflammatory Back Pain Service to provide assessment, diagnosis and prompt treatment for patients with axial spondyloarthropathies. Rheuamtology 2013; i166, 292

  28. Greenwood M, Baqai T, Cambridge S, Shaikh M, Rooney M, Donnelley S, Tahir H. Patient preferences for route of administration of Biologic therapies. Rheumatology 2013; i95; 104

  29. Combe W, Fitzgerald O, Tahir H, Gaylord S, Williams T, Pederson R, Valhos B, Kotak S. Impact of Etanercept- Methotrexate withdrawl on patient reported outcomes in patients with early rheumatoid arthritis (PRIZE Trial). Arthritis & Rheumatology; abstract 2359

  30. Casey G, Tierney C, Tahir H, Donnelley S, Bubbear J. Patient satisfaction with an associated teaching hospital clinical trial unit in north east London. Arthritis & Rheumatology; abstract 1925

  31. Shaikh M, Tahir H. Septic Sacroilitis mimicking an Inflammatory spondyloarthropathy. Rheumatology, vol 53, Supp 1, i61, April 2014

  32. Fattah Z, Tahir H, Ranganathan A, Bubbear J. Complete healing of traumatic multiple spinal fractures in a patient with Ankylosing Spondylitis who refused surgical intervention with teriparatide. Rheumatology, vol 53, Supp 1,i66, April 2014

  33. Shaikh MF, Baqai TJ, Tahir H. Acute brachial neuritis following influenza vaccination. BMJ Case Rep. 2012 Nov 28;2012. pii: bcr2012007673. doi: 10.1136/bcr-2012-007673.

  34. Shaikh M, Tahir H. Sacroilitis: an unusual cause for a common presentation. BMJ Case Rep. 2014 Sep 22;2014. pii: bcr2013203209. doi: 10.1136/bcr-2013-203209

  35. Tahir H, Mease P, McInnes I, Kirkham B, Kavanaugh A et al. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study. Rheumatology (2015) 54 (suppl 1): i137-i138 doi:10.1093/rheumatology/kev089.115

  36. Adshead R, Chua I, Donnelly SP, Tahir H. Ethnic Differences in Response to Anti-TNF in patients with Ankylosing Spondylitis Rheumatology (2015) 54 (suppl 1): i137-i138 doi:10.1093

  37. Adshead R., Tahir H and Donnelly S. A best practice UK model for Axial Spondyloarthritis diagnosis and treatment. European Medical Journal: In press.

  38. Raine C, Bubbear J, Tahir H. Polymyalgia Rheumatica. Foundation Year Journal 2015. Vol 9 (10);48-54

  39. Choida V, Donnelly S, Bubbear J, Fattah Z, Tahir H. Reactive Arthritis. Foundation Year Journal 2015. Vol 9 (10);61-66

  40. Kivitz A, Blanco R, Maradiago M, Sieper J, Tahir H, Readie A, Porter B. Secukinumab reduces signs and symptoms of active ankylosing spondylitis: Results from a 16 week, ransomised, placebo controlled phase 3 trial (Measure 3). PANLAR abstract 2016

  41. Zamani O, Combe B, Tony HP, Burson JS, Tahir H, Larsen E, Smolen J. Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to TNFi: summary results from the 24 week phase 3 RA –BEACON study. Rheumatol 2016

  42. Raine C, Tahir H, Donnelly S. Aggressive vasculopathy causing extensive gangrene in a patient with anti-RNP positive limited scleroderma/inflammatory arthritis overlap syndrome. Rheumatol 2016

  43. Etomi O, Chua I, Donnelly S, Tahir H. A survey of biologic prescribing habits amongst rheumatologists in London. Rheumatol 2016

  44. Kavanagh A, Mease P, Reimold A, Tahir H, Rexh J, Mpofu S. Secukinumab provides sustained imptovements in the signs and symptoms of active psoriatic arthritis: 2 year efficacy and safety results from the phase 3 randomised, double blind, placebo controlled trial (FUTURE 1). Submitted Arthritis Care and Research

  45. Wiland P, Dudler J, Veale D, Tahir H, Pederson R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S. The impact of withdrawn Etanercept-Methotrexate therapy on patient-reported outcomes in patients with early rheumatoid arthritis. Accepted Journal of Rheumatology

  46. Omid Zamani, Bernard Combe, Hans-Peter Tony, Juan Sanchez Burson, Hasan Tahir, Mikkel Østergaard, Beatrice Augendre-Ferrante, Anke Beselin, Esbjörn Larsson, Marta Casillas, and Josef Smolen. Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors: Summary Results from the 24-Week Phase III RA-Beacon Study. Rheumatology. 2016;55(suppl 1)

  47. Omid Zamani, Bernard Combe, Hans-Peter Tony, Juan Sanchez Burson, Hasan Tahir, Mikkel Østergaard, Beatrice Augendre-Ferrante, Anke Beselin, Esbjörn Larsson, Marta Casillas, Josef Smolen. EFICACIA Y SEGURIDAD DE BARICITINIB EN PACIENTES CON ARTRITIS REUMATOIDE ACTIVA Y RESPUESTA INADECUADA A FARMACOS ANTIRREUMATICOS MODIFICADORES DE LA ENFERMEDAD CONVENCIONALES (FAMEs): RESUMEN DE LOS RESULTADOS DEL ESTUDIO DE FASE III RA-BUILD DE 24 SEMANAS. Sociedad Espanola de Reumatologia - XLII Congreso Nacional. 2016

  48. Zamani O, Combe B, Tony HP, Burson JS, Tahir H, Østergaard M, Augendre-Ferrante B, Beselin A, Larsson E, Casillas M, Smolen J. Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: summary results from the 24-week phase 3 RA-BEACON study. Irish Society for Rheumatology Autumn congress, 2016

  49. Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. J Rheumatol. 2016 Jul;43(7):1268-77. doi: 10.3899/jrheum.151179. Epub 2016 Jun 1.

  50. Biro I, Etomi O, Barret J, Tahir H. Tick the tick: Arthritis in Lyme Disease. Foundation Year Journal 2017, vol 11 (2) 70-77

  51. Pakozdi A, Lewis MJ, Tahir H. How to approach Vasculitis- a clinical guide. Foundation Year Journal 2017, vol 11 (2) 78- 87

  52. Biro I, Etomi O, Pakozdi A, Tahir H. Management of common soft tissue disorders. Foundation Year Journal 2017, vol 11 (2) 88 -96

  53. Wodehouse T, Poply K, Ramaswamy S, Snidvongs S, Bourke J, Tahir H, Ullrich K. A pilot study investigating whether quantitative sensory testing alters treatment bin patients with fibromyalgia. British Journal of Pain awaiting publication

  54. Biro I, Bubbear J, Donnelly S, Fattah Z, Sarkodieh J, Ranganathan A, Tahir H. Teriparatide and vertebral fracture healing in Ankylosing Spondylitis. Trauma case reports 2017. vol 12, 34-39

  55. Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Readie A, Pricop L, Abrams K. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018 Mar 17. pii: annrheumdis-2017-212687. doi: 10.1136/annrheumdis-2017-212687.

  56. Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Pricop L, Andersson M, Readie A, Porter B. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017 Dec 22;19(1):285. doi: 10.1186/s13075-017-1490-y.

  57. Tahir H, Deodhar A, Genovese M, Takeuchi T, Aelion J, Van den Bosch F, Haemmerle S, Richards HB. Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.Rheumatol Ther. 2017 Dec;4(2):475-488. doi: 10.1007/s40744-017-0086-y. Epub 2017 Nov 14.

  58. Tahir H, Biro I, Donnelly S, Greenwood M. Randomised, prospective, non-blinded pilot study comparing the effect of intramuscular steroid injections and intralesional steroid injections in the management of tennis elbow.BMJ Open Sport Exerc Med. 2017 Feb 10;2(1):e000126. doi: 10.1136/bmjsem-2016-000126. eCollection 2016.

  59. Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S Dr. Wiland, et al, reply. J Rheumatol. 2017 Feb;44(2):259. doi: 10.3899/jrheum.161405.

  60. Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, Geusens P, Wang Z, Pricop L, Mpofu S; FUTURE-1 Study Group. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study. Arthritis Care Res (Hoboken). 2017 Mar;69(3):347-355. doi: 10.1002/acr.23111.

  61. Tahir H. Novel therapies in ankylosing spondylitis – from clinical trials to clinical practice. Submitted Rheumatology.

  62. Mease P, Brodie G, Kavanagh A, Reimold A, Tahir H, Hall S, Geusens P, Pellet P, Delicha E, Mpofu S, Pricop L. Secukinumab in the treatment of psoriatic arthritis: Efficacy and safety results through 3 years from the year 1 extension of the phase 3 Future 1 trial. Submitted The Journal of Rheumatology 2017-1374.R1.

  63. Pakozdi A & Tahir H. Comment on BSR and BHPR guideline for the prescription and monitoring of non-biologic disease modifying anti-rheumatic drugs. Rheumatology Advances in Practice 2017;0:1-2 doi:10. 1093/rap/rkx009